If you are wondering what is the difference in between Health Evolution formulas and Humanofort, there are very significant differences:
WHEN TAKING SUPPLEMENTS, THE BIG QUESTIONS ARE AROUND PURITY OF CONTENTS, QUALITY OF CONTENTS, AND QUANTITY OF CONTENTS.
There are three main problems with Humanofort.
1. Humanofort is manufactured in Romania, which is rated very poor for food safety and ingredients made there are not regulated in the US, the UK, Australia, nor European countries such as Germany.
2. The Humanofort ingredient does not have Young Tissue Extract's reputation nor clinical trials … the fact that it’s from Romania is enough to prevent usage.
Romania is not rated highly in terms of food security and contamination, eg ranking at #52 (very low) for quality and safety https://foodsecurityindex.eiu.com/Country/Details#Romania.
Compare that to Norway which ranks at #2 https://foodsecurityindex.eiu.com/Country/Details#Norway
And the US which ranks at #4 https://foodsecurityindex.eiu.com/Country/Details#United%20States.
3. Even if Humanoforte contained active ingredient - and there's a lack of clarity around what it does contain - Humanofort does not contain a fraction of the quantity of what we include of Young Tissue Extract.
I have been given access to a Certificate of Analysis of the GrowthCell/Humanoforte ingredient, which shows 5.3% protein compared to Young Tissue Extract's 80% protein!
This ingredient from Humanoforte/Growthcell is not rated as credible.
Humanofort has either 30 or 60 capsules per bottle. A bottle is sold as one month's supply.
Each capsule claims to contain 100mg of "oligopeptides", unlike Health Evolution's full clinical dose of 1600mg Young Tissue Extract.
Humanoforte is a “proprietary blend” and their patent says the blend contains “20 parts of embryonic extract”, ie 20mg per serving of Humanofort.
ie 20mg x 30 days = 600mg of their "embryonic extract" in a whole bottle of 30 capsules, or 1200mg in a 60 capsule bottle.
EACH YOUNG TISSUE EXTRACT SERVING IS 1600MG PER DAY - SO THERE ARE 48,000MG PER BOTTLE.
IE 1600MG X 30 DAYS = 48,000MG /BOTTLE.
The majority of the Growthcell ingredient is maltodextrin, a cheap and common filler for processed foods.
A repackaged version of Humanofort is GrowthCell, but GrowthCell contains only 30 capsules per bottle, each containing 100mg of the Humanofort "blend".
Humanofort was previously promoted by actor and bodybuilder Emeric Delczeg.
A claim was made that Humanofort was previously produced and sold in the US by Swansons - this is incorrect, because Swansons used to sell Young Tissue Extract until Health Evolution gained exclusivity of Young Tissue Extract.
Some other claims have been made regarding testing regarding the effect of human cells grown in vitro (test tubes). These tests are not considered credible.
The Humanofort product is not considered credible for all the reasons listed above.
TO ORDER HEALTH EVOLUTION FORMULAS, WHICH CONTAIN FULL CLINICAL THERAPEUTIC DOSE OF GENUINE YOUNG TISSUE EXTRACT, BACKED BY DOCTORS AND YEARS OF RESEARCH, AND WITH 60 DAYS FULL-MONEY BACK TRIPLE GUARANTEES, GO TO THIS PAGE: HTTPS://HEALTHEVOLUTIONPROJECT.COM/COLLECTIONS
Notes:
Humanofort patent:
According to the patent: “vii) mixing the embryo-peptides and denatured embryo-proteins back together at a 1 to 4 ratio to produce the embryonic extract;”
“Composition with increased bioavailability of orally administrated embryo-peptides according to the invention is the following: 20 parts of heterologous embryonic extract, standardized in embryo-peptides, 80 parts of maltodextrin, 2 parts selenium yeast containing 750 mg Se per kg, 1.5 part chromium yeast containing 900 mg Cr per kg, 0.2 parts of zinc chelated in embryo-peptides, 0.2 parts vitamin B6, pyridoxine, 0.5 parts of cationic peptides mixture, formed by enzymatic hydrolysis, of the vitellus and of the egg white, remaining after harvesting the chickens embryos, which have a specific antitrypsin activity, of 980±53.3 BAEE units per mg of peptide, and intestinal epithelium endocytosis promoting activity, 0.5 parts of sodium taurocholate, 0.01 . . . 0.015 parts of expanded silicon dioxide, 0.01 . . . 0.015 parts of magnesium stearate, 0.01 . . . 0.015 parts of methylparaben and 0.005 parts . . . 0.010 parts of propylparaben, parts being expressed in units of weights.
The process for obtainment of the compositions with increased bioavailability of orally administrated embryo-peptides according to the invention includes the following steps: obtainment of the biological material with a very low biological contamination, by aseptic harvesting of chicken embryos, together with chorioallantoic membranes, from eggs fertilized and incubated for 10 days, or disinfection of the silkworm moth (insect) non-diapause eggs, or aseptic harvesting of the drone brood/male larvae of Apis melifera (insect), at 10 days after haploid eggs laying, more exactly of larvae old of 7 days; disintegration of the biological material by using a colloidal mill and determination of the dry matter content into the extract; dilution of 10 parts of disintegrated embryos, expressed as dry matter, with 90 parts of sterile distilled water; homogenization of the diluted disintegrated embryos with a piston homogenizer at high pressure, two cycles at 50 MPa; mixing 100 parts of the resulting suspension with 1.25 parts zinc carbonate and ultrasonication for 25 min at 500 W, to assure the dissociation of growth factors and their receptors; removal of excess zinc carbonate and of cellular debris by centrifugation; embryo-peptides from supernatant concentration by tangential ultrafiltration through a 10 kDa membrane; denaturation of the protein, from the ultrafiltration retentate, which have a molecular weight >10 kDa, by heating to 85° C. for 25 min; mixing of ultrafiltration dialysate which contain embryo-peptides <10 kDa, with ultrafiltration retentate with denatured protein >10 kDa, in ratio 1 part peptides to 9 parts protein in the case of chickens embryos, and 1 part peptides to 4 parts protein in the case of biological material originating from the early stages of insect development, and homogenization on a piston homogenizer, 1 cycle to 30 MPa; enzymatic hydrolysis with endo-protease of vitellus and egg white remaining after harvesting the chickens embryos, in a ratio of 2 parts endo-protease per 100 parts of vitellus and egg white remaining after harvesting the chickens embryos, followed by tangential ultrafiltration of the peptides with a molecular weight of less than 10 kDa, absorption from ultrafiltrate dialysate of the formed cationic peptides, on a cation exchange resin, elution of the cationic peptides from the ion exchange resin and determination of peptide concentration with Folin-Ciocâlteu reagent; adding over the specific amount of eluate containing 0.5 parts of cationic peptides, which have a specific antitrypsin activity, of 980±53.3 BAEE units per mg of peptide, and intestinal epithelium endocytosis promoting activity, of 80 parts maltodextrin, 2 parts selenium yeast containing 750 mg Se per kg, 1.5 part chromium yeast containing 900 mg Cr per kg, 0.2 parts vitamin B6, pyridoxine, 0.5 parts sodium taurocholate, 0.01 . . . 0.015 parts expanded silicon dioxide, 0.01 . . . 0.015 parts magnesium stearate, 0.01 . . . 0.015 parts methylparaben and 0.005 parts . . . 0.010 parts propylparaben and mixing with 20 parts of embryo-peptide-denatured embryonic protein mixture containing also 0.2 parts of zinc chelated in embryo-peptides; homogenization of the resulted mixture by using a piston homogenizer at high pressure, 2 cycles at 35 MPa; spray-drying of the final mixture, at max. 10 kg/h, using a centrifugal atomizer operated at 20,000 rpm, at an air inlet temperature of 140 . . . 150° C. and an air outlet temperature of 80 . . . 85° C.”